Next Article in Journal
Effect of Different Green Extraction Methods and Solvents on Bioactive Components of Chamomile (Matricaria chamomilla L.) Flowers
Previous Article in Journal
Targeting Tumors Using Peptides
Open AccessArticle

Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles

by Tim Tome 1,2, Zdenko Časar 1,2,* and Aleš Obreza 1,*
1
Faculty of Pharmacy, University of Ljubljana, Aškerčeva c. 7, SI-1000 Ljubljana, Slovenia
2
Analytics Department, Sandoz Development Center Slovenia, Lek Pharmaceuticals d.d., Verovškova ulica 57, SI-1526 Ljubljana, Slovenia
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(4), 809; https://doi.org/10.3390/molecules25040809 (registering DOI)
Received: 24 January 2020 / Revised: 11 February 2020 / Accepted: 12 February 2020 / Published: 13 February 2020
(This article belongs to the Special Issue Drug Analysis in Pharmaceutical Development and Drug Manufacturing)
This article presents the development of a reversed-phase (RP) high-performance liquid chromatographic (HPLC) method for determination of process-related impurities in a celecoxib drug substance following Analytical Quality by Design (AQbD) principles. The method from European Pharmacopeia (EP) for celecoxib drug substance does not sufficiently separate celecoxib from its EP impurity B because the system suitability criterion is not achieved (resolution NLT 1.8). The same issue was observed with the proposed method from United States Pharmacopeia (USP) for celecoxib capsules, where EP impurity A elutes under the main peak. A new HPLC method was developed that eliminates the disadvantages of the two pharmacopeial methods and is capable of efficiently separating and determining all seven impurities listed in EP and the proposed USP monographs. The development of a new HPLC method started with method scouting, in which various C18 and phenyl stationary phases were tested. Improved selectivity was obtained only with a chiral stationary phase. An immobilized Chiralpak IA-3 column used in RP mode turned out to be the most appropriate for method optimization. The ratio of acetonitrile in the mobile phase, flow rate, and column temperature were recognized as critical method parameters (CMPs) and were further investigated using a central composite face response-surface design. A multiple linear regression (MLR) method was applied to fit the mathematical models on the experimental data to determine factor–response relationships. The models created show adequate fit and good prediction abilities. The Monte Carlo simulation method was used to establish the design space. The method developed was verified in terms of precision, sensitivity, accuracy, and linearity, and the results showed that the new method is suitable for determination of seven process-related impurities of celecoxib. View Full-Text
Keywords: RP-HPLC; AQbD; HPLC method development; HPLC method optimization; pharmacopeia; celecoxib RP-HPLC; AQbD; HPLC method development; HPLC method optimization; pharmacopeia; celecoxib
Show Figures

Graphical abstract

MDPI and ACS Style

Tome, T.; Časar, Z.; Obreza, A. Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles. Molecules 2020, 25, 809.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop